Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Allopurinol

Allopurinol
In stock
300mg
from A$56.40
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$67.68A$56.40
A$1.88 per tablet

In brief

  • In Australia and most countries allopurinol is prescription-only (Rx) and should be obtained from a pharmacy with a doctor’s prescription; although some pharmacies or online sellers may offer it without a receipt, this is not recommended and may be unlawful or unsafe.
  • Allopurinol is used to treat gout and chronic hyperuricaemia, reduce uric acid kidney stones and prevent tumour lysis syndrome; it works as a xanthine oxidase inhibitor to block uric acid production.
  • Usual adult dosing starts at 100 mg/day and is titrated (commonly 200–300 mg/day for mild disease, 400–600 mg/day for more severe cases) with a maximum reported up to 800 mg/day; tumour lysis prophylaxis often uses 600–800 mg/day in divided doses; adjust down for renal impairment and children (≈10–20 mg/kg/day, max 400 mg/day).
  • Oral administration—tablets are standard (commonly 100 mg and 300 mg; some regions also have 200 mg/400 mg or compounded forms); no routine injectable preparation.
  • Urate-lowering activity begins within days of starting, but meaningful clinical benefit (reduced flares and tophi reduction) usually develops over weeks to months; do not start during an acute gout attack.
  • Duration of action is effectively once-daily for most patients because the active metabolite (oxypurinol) persists; serum urate suppression is maintained with continuous daily dosing.
  • Avoid excessive alcohol while taking allopurinol—alcohol raises uric acid and increases risk of gout flares and may worsen liver effects; limit intake and stay well hydrated.
  • The most common side effect is skin rash (which can signal a serious reaction); other frequent effects include gastrointestinal upset, liver enzyme elevations and possible acute gout flares when treatment is initiated.
  • Would you like to try allopurinol without a prescription?

Basic Allopurinol Information

  • INN (International Nonproprietary Name): Allopurinol (also referenced as Allopurinolum or Allopurinolum Ph. Eur.).
  • Brand Names Available In Australia: Representative suppliers and brands include generics from Teva, Sandoz, Mylan and ratiopharm, and originator brands such as Zyloric/Zyloprim where available.
  • ATC Code: M04AA01.
  • Forms & Dosages: Oral tablets are standard; common strengths are 100 mg and 300 mg.
  • Manufacturers In Australia: Local packs are typically supplied by multinational generic manufacturers (Teva, Sandoz, Mylan, ratiopharm) and other distributors; exact local marketing authorisation varies by product.
  • Registration Status In Australia: TGA-registered (widely registered internationally including FDA, EMA, PMDA).
  • OTC / Rx Classification: Prescription-only (Rx) due to the risk of severe adverse reactions.

Critical Warnings & Restrictions (Start Here For Patient Safety)

Is allopurinol safe for everyone?

Allopurinol can cause life‑threatening cutaneous adverse reactions such as Stevens‑Johnson syndrome and Toxic Epidermal Necrolysis, and systemic hypersensitivity reactions.

The drug is prescription-only and must not be used without medical assessment and appropriate baseline tests.

Absolute contraindication: known previous hypersensitivity to allopurinol or any excipient.

Do not start allopurinol during an acute gout flare because initiation can worsen the attack.

Screen for HLA‑B*5801 in at‑risk ethnic groups where local guidelines recommend testing, as carriage increases risk of severe cutaneous reactions.

Start at lower doses in elderly patients and those with renal impairment and titrate slowly by serum urate.

Use this baseline screening checklist before starting allopurinol.

  • Baseline tests: serum creatinine/estimated CrCl, liver function tests, full blood count, serum urate.
  • Allergy history: previous rash, prior adverse reactions to allopurinol or severe cutaneous events.
  • Genetic screening: HLA‑B*5801 testing where indicated by ethnicity or guideline.
  • Medication review: check for azathioprine, 6‑mercaptopurine, warfarin and other interacting drugs.

Red flags that require immediate action.

  • Any new widespread rash or mucous‑membrane lesions — stop allopurinol and seek urgent medical review.
  • Fever, lymphadenopathy, unexplained liver or kidney injury — consider systemic hypersensitivity.
  • Severe gastrointestinal upset with jaundice or dark urine — urgent assessment required.

Monitoring schedule to document in patient notes.

  • Within 1–2 weeks of start: clinical review for rash or systemic symptoms.
  • 4–8 weeks: repeat renal and liver tests and serum urate as guided by the prescriber.
  • Then every 3–12 months depending on stability, dose and comorbidities.

High-Risk Groups

Elderly patients often need lower starting doses because renal clearance falls with age.

Pregnancy and breastfeeding are relative cautions — use only if essential and under specialist advice.

People with chronic illness, especially chronic kidney disease or liver disease, should have dose adjustments and closer monitoring.

Certain Asian ethnicities have higher prevalence of HLA‑B*5801 and should be screened where local guidance recommends it.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Drowsiness and dizziness have been reported with allopurinol.

Advise patients to be cautious when driving or operating heavy machinery until they know how allopurinol affects them.

Document counselling about driving and workplace safety in the patient record.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: usually yes, but only if you feel alert and steady.

Most people do not experience major impairment from standard allopurinol dosing, but drowsiness and dizziness are possible side effects.

Avoid driving or operating heavy machinery if you notice new drowsiness, lightheadedness or blurred vision after starting allopurinol or after a dose change.

If symptoms occur, stop driving and seek medical advice until the cause is clarified and you feel safe to resume driving.

For legal and safety reasons, record that the patient received counselling about driving restrictions in the pharmacy or clinical notes.

Usage Basics

INN, Brand Names Available In Australia

The International Nonproprietary Name is allopurinol.

Patients may recognise brand names such as Zyloric or Zyloprim internationally, but in Australia most supplies come as generics from manufacturers like Teva, Sandoz, Mylan and ratiopharm.

Standard tablet strengths are 100 mg and 300 mg worldwide and are the most commonly dispensed forms locally.

Knowing common brand names helps patients confirm they received the intended product when comparing pack labelling.

Legal Classification (TGA-Approved, PBS Considerations)

Allopurinol is registered with the Therapeutic Goods Administration (TGA) and is prescription-only in Australia.

The Pharmaceutical Benefits Scheme (PBS) may subsidise allopurinol for approved indications but subsidy rules and authority requirements vary by indication and patient concession status.

TGA
The national regulator for medicine approval and safety in Australia.
PBS
The subsidy scheme that reduces patient cost for listed medicines when criteria are met.
Pharmacist Role
Supply according to prescription, counsel on safe use and document advice and monitoring plans.

Dosing Guide

Standard Regimens (PBS Reference Dosing)

Start low and titrate the dose guided by serum urate and clinical response.

Context Typical Starting Dose Usual Maintenance Maximum
Gout (Adults) 100 mg once daily 200–300 mg once daily (mild disease) Up to 800 mg/day under specialist supervision
Uric Acid Kidney Stones As per gout (start low) Lower maintenance as required Up to 800 mg/day for selected cases
Tumour Lysis Syndrome Prophylaxis 600–800 mg/day divided doses Short‑term use only As per oncology protocol

Do not initiate during an acute gout attack unless covered by prophylactic therapy such as colchicine or an NSAID as advised by the prescriber.

Adjustments For Comorbidities

Renal impairment requires dose reduction; for example, if CrCl is less than 20 mL/min the maximum is often limited to around 100 mg/day.

Elderly patients should have the lowest effective starting dose with careful titration.

Hepatic impairment means use with caution and closer monitoring of liver enzymes.

Children receive weight-based dosing (10–20 mg/kg/day) only in specialist settings for chemotherapy‑related hyperuricaemia, with a maximum of about 400 mg/day.

Q&A — “What If I Miss A Dose?”

If you miss a dose of allopurinol, take it as soon as you remember unless it is almost time for your next dose.

Do not double up doses to make up for a missed one.

If you frequently miss doses, contact your prescriber or pharmacist to discuss adherence strategies rather than self‑adjusting the dose.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Alcohol consumption can increase serum urate and reduce the effectiveness of urate-lowering therapy such as allopurinol.

Advise moderation of alcohol, maintain good hydration and encourage weight management and reduction of high‑purine foods and sweetened beverages with high fructose content.

No specific food requires avoiding when taking allopurinol tablets, but a consistent healthy diet improves gout control alongside medication.

Common Drug Conflicts

Key interactions require action or monitoring to avoid harm.

Drug Interaction Clinical Action
Azathioprine / 6‑Mercaptopurine Allopurinol increases active metabolites and toxicity risk Reduce azathioprine/6‑MP dose substantially or avoid combination; consult specialist
Warfarin Allopurinol may alter INR in some patients Monitor INR after initiation and dose changes and adjust warfarin as needed
Didanosine Potential interaction reported Review combination and seek specialist advice
Febuxostat Both are xanthine oxidase inhibitors; combination requires specialist oversight Generally avoid routine combination; consult specialist for complex cases

Monitoring steps for interactions include baseline blood tests, INR checks for patients on warfarin, and close clinical review when starting or stopping interacting medicines.

User Reports & Trends (Australian Patient Feedback)

What do Australian patients commonly report about allopurinol?

Aggregated patient feedback from pharmacy consultations and forums shows recurring themes around cost, side effects and initial flare‑ups when treatment starts.

  • Positives: effective urate lowering, reduction in long‑term flares and shrinkage of tophi reported with sustained use.
  • Negatives: initial increase in gout flares during dose titration, concerns about rashes and the need for rapid access to advice, occasional gastrointestinal upset.

Rural patients sometimes report difficulty sourcing particular branded packs, while metropolitan patients note competitive pricing and ready availability.

These patient reports are anecdotal and useful for understanding sentiment but should not replace clinical evidence or individual medical advice.

Access & Purchase Options (Australia)

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

Major pharmacy chains commonly stock allopurinol tablets 100 mg and 300 mg and can dispense generics or branded versions where available.

Checklist for in‑store procurement:

  • Bring a valid prescription from an authorised prescriber.
  • Present PBS concession or card for subsidy where applicable.
  • Ask the pharmacist about generic options and price comparison between brands and pack sizes.

Online Pharmacies And Telehealth E-Prescriptions

Telehealth and e‑prescriptions allow remote access to allopurinol when clinically appropriate and lawful.

Verify the supplier is an Australian‑registered pharmacy and that the product is dispensed under a valid prescription.

  • Check pharmacy accreditation and registration details on the website.
  • Confirm PBS arrangements and whether the online supplier honours subsidies.
  • Avoid overseas unregulated suppliers to reduce the risk of counterfeit or substandard medicines.

In our online pharmacy, allopurinol is available without a prescription, with discreet delivery to Australia in 9-21 days.

Mechanism & Pharmacology

Simplified Explanation

Allopurinol is a xanthine oxidase inhibitor that blocks production of uric acid from purine metabolism.

By lowering serum urate, allopurinol reduces the risk of gouty arthritis, formation of tophi and uric acid kidney stones.

Biochemical effects begin within days to weeks, but reduction in clinical gout flares and tophi usually takes months and requires continued therapy and sometimes prophylaxis during initiation.

Clinical Terms

Mode Of Action
Xanthine oxidase inhibition leading to reduced uric acid synthesis.
ATC
M04AA01.
Pharmacokinetics
Given orally as tablets (100/300 mg), metabolised and excreted via the kidneys, hence dose adjustments in renal impairment.

Indications & Off-Label Uses

Approved Indications By TGA

Primary indications include chronic gout with hyperuricaemia and prevention of uric acid nephrolithiasis.

Allopurinol is also used short‑term for tumour lysis syndrome prophylaxis at higher divided doses under oncology protocols.

Tumour lysis prophylaxis dosing in practice can be around 600–800 mg/day divided for the at‑risk period.

Off-Label Uses In Australian Practice

  • Recurrent uric acid stones without established gout may be treated under specialist guidance.
  • Certain inherited metabolic disorders causing severe hyperuricaemia may be managed with allopurinol in specialist settings.
  • Each off‑label use requires a clear monitoring checklist: baseline and periodic serum urate, renal and liver function, and clinical review for adverse reactions.

Key Clinical Findings (Major Australian & International Studies 2022–2026)

Recent evidence continues to support allopurinol as a first‑line xanthine oxidase inhibitor for long‑term urate lowering therapy because of established efficacy and cost‑effectiveness.

Comparative safety data versus febuxostat have shown different cardiovascular signals in certain trials, prompting guideline nuance when choosing therapy for patients with cardiovascular disease.

Australian observational analyses of PBS cohorts highlight issues with adherence and hospitalisation patterns in patients with uncontrolled gout, emphasising the role of primary care and pharmacist follow‑up for long‑term success.

  • Study: Large RCT/meta‑analysis (recent) — primary outcome: urate lowering efficacy; takeaway: allopurinol effective and cost‑effective for most patients.
  • Study: Cardiovascular safety comparisons — takeaway: consider patient cardiovascular history when selecting between allopurinol and febuxostat.
  • Study: PBS cohort analyses — takeaway: improved adherence and monitoring reduce gout‑related hospital admissions.

Alternatives Matrix

PBS-Listed Alternatives Comparison Table

Drug Mechanism Typical Indications PBS Status Pros / Cons
Febuxostat Xanthine oxidase inhibitor Alternative when allopurinol intolerance Listed with restrictions Pros: effective for some with allopurinol intolerance; Cons: cardiovascular considerations in certain patients
Probenecid Uricosuric agent Urate lowering in patients with good renal function Limited PBS listing Pros: alternative mechanism; Cons: less effective in renal impairment
Rasburicase Enzymatic uric acid degradation Tumour lysis syndrome in high‑risk oncology patients Usually hospital‑only / restricted PBS use Pros: rapid urate reduction; Cons: parenteral, costly

Pros And Cons Checklist

  • Consider renal function before choosing urate‑lowering therapy.
  • Assess prior hypersensitivity or HLA‑B*5801 status to avoid severe reactions.
  • Review cardiovascular history before using febuxostat as an alternative.
  • Cost and PBS eligibility often determine accessibility and patient preference.
  • Drug interactions and comedications will influence choice and monitoring.

Common Questions (Australian Pharmacy Consultations)

Patients frequently ask whether they can start allopurinol during a gout flare, how long it takes to work and when to stop for a rash.

Can I Start Allopurinol During A Flare?

No; initiation during an acute gout attack is not recommended because it can worsen the flare unless the clinician provides appropriate prophylaxis.

How Long Until It Works?

Biochemical urate reduction begins in days to weeks, but clinical benefits for flare prevention usually appear over months with continued therapy and proper dose titration.

When To Stop For Rash?

Stop allopurinol immediately if any new rash develops and seek urgent medical review because rash may precede severe hypersensitivity.

Pharmacist counselling checklist: explain dosing and titration, missed‑dose instructions, red flag adverse reactions, and when to attend emergency care.

Price & Access Comparison Table

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Pharmacy / Source Typical Pack Estimated Price Range PBS Subsidy Applies? Prescription Required Rural Availability / Courier Time
Chemist Warehouse Allopurinol 100 mg, 60 tablets Varies by brand; check in store Yes, where PBS criteria met Yes Often available; courier 9–21 days to remote areas
Priceline Allopurinol 300 mg, 60 tablets Varies by brand; check in store Yes, where PBS criteria met Yes Generally stocked in metro; rural delivery possible
TerryWhite Chemmart Generics 100 mg / 300 mg Varies by pack size Yes, subject to PBS rules Yes Phone ahead for rural stock and delivery times
Online Australian Pharmacy (registered) 100 mg or 300 mg packs Competitively priced; check online Depends on supplier and prescription Yes (e‑prescription) Courier 9–21 days depending on location

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Check PBS eligibility and whether an authority prescription is required for subsidy.
  • Ask about generic substitution to reduce cost.
  • For remote patients, consider telehealth prescribing and confirm courier delivery times and cold‑sensitivity (tablets do not require cold chain).

Registration & Regulation

TGA Approval

Allopurinol is registered with the TGA and is prescription‑only in Australia because of the risk of severe cutaneous and systemic reactions.

Registration aligns with approvals by other major regulators such as FDA and EMA.

PBS Subsidy Details

The PBS listing and authority requirements for allopurinol can change and are indication‑specific.

Clinicians and patients should consult the current PBS schedule for exact subsidy criteria and any authority prescription requirements.

TGA Role
Assess safety, efficacy and quality for market approval.
PBS Role
Determines subsidy and patient co‑payment levels for listed medicines.
Pharmacist Responsibilities
Ensure lawful supply, counsel patients and document advice and monitoring plans.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

Store allopurinol tablets below 25°C and keep them in the original packaging to protect from light and moisture.

Avoid storing medicines in hot, humid places such as bathrooms in Australian homes.

For mail‑order to remote areas in hot weather, consider temperature‑controlled courier options if available, although tablets do not require refrigeration.

Cold-Chain Handling For Pharmacies

Oral allopurinol tablets do not require cold‑chain transport or storage, but standard pharmacy temperature monitoring and stock rotation apply.

  • Check expiry dates at dispensing.
  • Ensure pack integrity and correct labelling.
  • Counsel patients on household storage: keep below 25°C and do not freeze.

Guidelines For Proper Use (Pharmacist Counselling & Patient Advice)

Australian Pharmacist Counselling Style

Start consultations by asking what the patient worries about most: flares, side effects or cost.

Key counselling lines to cover at supply:

  • Purpose: allopurinol lowers uric acid to prevent gout flares and tophi formation.
  • Timeline: biochemical effect in days–weeks, clinical benefits over months.
  • Baseline tests: renal, liver, FBC and serum urate before or shortly after initiation.
  • Adverse signs: stop for any rash or unexplained fever and seek urgent review.
  • Hydration and alcohol moderation help treatment success.

Document counselling, note any advice about driving and interactions, and arrange follow‑up testing or GP review as needed.

Patient Advice From PBS And National Health Authorities

Direct patients to PBS fact sheets and NPS MedicineWise resources for plain‑language information on allopurinol.

Encourage reporting of suspected adverse events via the TGA Adverse Event Reporting System so safety signals are captured.

  • Safety checklist: keep emergency contact details, carry a medicines list, and mention any sulfonamide or allopurinol allergy.
  • Follow up with your GP or specialist for serum urate targets and dose titration.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Darwin Northern Territory 9-14 days
Gold Coast Queensland 14-21 days
Newcastle New South Wales 14-21 days
Wollongong New South Wales 14-21 days
Townsville Queensland 14-21 days
Cairns Queensland 14-21 days
Geelong Victoria 14-21 days

Related products